<DOC>
	<DOCNO>NCT01423318</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group study evaluate safety pharmacokinetics subcutaneous lebrikizumab healthy Japanese volunteer . Healthy Japanese Caucasian volunteer randomize receive single subcutaneous dose either lebrikizumab placebo .</brief_summary>
	<brief_title>A Study Lebrikizumab Healthy Japanese Caucasian Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult healthy male female , 18 55 year age inclusive Caucasian , Japanese , nonJapanese subject . Caucasian nonJapanese subject parent grandparent Japanese descent ; Japanese subject must first , second third generation Body weight 45 105 kg , inclusive In good health , determine clinically significant finding medical history , 12lead ECG , vital sign , laboratory evaluation Fertile male woman childbearing potential must use appropriate form contraception screen 60 day study completion Negative hepatitis B , hepatitis C , HIV infection Negative select drug abuse screening ( include alcohol ) checkin ( include alcohol ) Pregnant lactate woman History clinically significant drug allergy and/or know hypersensitivity study drug formulation component History helminthic infection travel within past 3 month area high risk parasitic exposure Use prescription drug include inhale , oral , parenteral corticosteroid and/or beta agonist , within 7 day prior dose study Use tobacco nicotinecontaining product 7 day prior checkin , result urinary cotinine &gt; 500 ng/mL . Minimal/intermittent smoking permit study Participation investigational drug trial receipt investigational study drug occur within 30 day 5 halflives , whichever longer , prior checkin ( Day 1 ) History significant , chronic , recurrent infection require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>